List of Excipients in Branded Drug LUPKYNIS

Subscribe to access the full database, or Start Trial
Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Aurinia Pharma US Inc	LUPKYNIS	voclosporin	75626-001	ALCOHOL	2026-01-22
Aurinia Pharma US Inc	LUPKYNIS	voclosporin	75626-001	MEDIUM-CHAIN TRIGLYCERIDES	2026-01-22
Aurinia Pharma US Inc	LUPKYNIS	voclosporin	75626-001	POLYSORBATE 40	2026-01-22
Aurinia Pharma US Inc	LUPKYNIS	voclosporin	75626-001	TOCOPHERSOLAN	2026-01-22
>Company	>Tradename	>Ingredient	>NDC	>Excipient	>Potential Generic Entry

Last updated: July 30, 2026

LUPKYNIS (voclosporin) excipient strategy and commercial opportunities for generics, biosimilars, and reformulations

Executive summary: LUPKYNIS (voclosporin) is a proprietary, small-molecule calcineurin inhibitor in capsules, with exclusivity and patent protections that generally extend beyond the immediate term for most generic and reformulation entries. Commercial opportunities are most practical in (i) authorized generic or supply deals aligned with brand life-cycle management, (ii) patent-risk-graded reformulations that change excipient systems while minimizing the likelihood of infringing composition-of-matter or process claims, and (iii) formulation “design-around” work targeted at manufacturability, stability, and patient-experience improvements rather than core therapeutic equivalence. For stand-alone product launches, the main barrier is not excipient selection alone, but the overall patent estate plus regulatory requirements for bioequivalence and interchangeability under FDA’s Abbreviated New Drug Application pathway.

What excipients are used in LUPKYNIS capsules and why does the excipient system matter?

Core point: Excipient choice in LUPKYNIS capsules impacts dissolution behavior, hygroscopicity control, stability, powder flow, fill-weight uniformity, and in-process controls. For a calcineurin inhibitor like voclosporin, formulation work usually focuses on protecting an active that can be sensitive to moisture, temperature, and light, while ensuring consistent drug release and predictable absorption.

Typical excipient strategy for oral calcineurin inhibitor capsules

While the exact LUPKYNIS excipient list is fixed by the approved NDA formulation and manufacturer-specific components, the commercial and technical pattern for similar oral small-molecule capsule products is consistent:

Moisture management: protective binders and/or coatings, moisture-impermeable packaging strategy, and excipient selection to reduce water uptake.
Release control: disintegrants and film-formers tuned to achieve a dissolution profile compatible with bioequivalence.
Powder flow and content uniformity: glidants, lubricants, and flow agents to support capsule filling and minimize segregation.
Stability protection: antioxidants or stabilizing excipients if compatibility signals require them.
Manufacturing robustness: processing aids that reduce sensitivity to batch-to-batch variation and lower rejection rates during scale-up.

How excipient strategy affects generic risk

For generics, excipients can be the practical differentiator in two ways:

Bioequivalence sensitivity: Even when the API is unchanged, excipient-driven dissolution differences can affect Cmax and AUC, creating bioequivalence risk.
Litigation leverage: If the brand’s patent estate includes formulation or process claims, a “different excipient” approach may reduce infringement risk only where claims are not drawn broadly to the composition or to the claimed manufacturing method.

Business implication: excipient changes alone do not eliminate patent exposure unless the relevant claims are narrow to specific compositions, specific particle engineering, or specific manufacturing steps.

What patents protect LUPKYNIS capsules and formulations, and how do excipients factor into claim scope?

Executive answer: Patent risk for reformulation and generic entry is driven by the active ingredient patent estate first. Excipients matter mainly if the brand has formulation, solid-state, particle, or manufacturing method claims that read on the claimed capsule composition or the claimed process.

Patent estate mapping: where excipients can become relevant

In small-molecule oral products, the most common formulation-related claim families include:

Solid-state form claims (polymorphs, solvates, amorphous forms) where excipients may influence stability but do not change the API form.
Particle size or morphology claims that may depend on manufacturing and milling steps, not just capsule excipients.
Coating or microencapsulation claims that can include excipient layers and specific film-former systems.
Manufacturing method claims where the process parameters and excipient mixing order are part of infringement analysis.

Commercial takeaway for an excipient strategy

If the active is still under composition-of-matter protection, excipient design is secondary to regulatory strategy.
If the active-form patents are expired but formulation/process patents remain, excipient changes can be used for design-around while preserving bioequivalence targets.

When does LUPKYNIS lose exclusivity, and what does that mean for excipient-driven reformulations?

Executive answer: Exclusivity timing and patent expiration determine the launch window; excipient strategy governs feasibility and reduces technical risk for a launch once regulatory and patent barriers clear.

Key timelines that determine entry feasibility

A launch window is typically driven by:

Orange Book patent expirations (composition-of-matter, method-of-use, formulation/process if listed)
Patent term adjustments and exclusivity extensions
Data exclusivity under the NDA
Regulatory interchangeability considerations (generic substitution and labeling)

How to position excipient opportunities relative to patent “cliff”

Pre-expiry: best business posture is usually life-cycle support (authorized variants, patient-friendly improvements) rather than an at-risk launch.
Post-expiry: excipient-driven work becomes commercially actionable because regulatory entry can occur without direct infringement risk if patents are expired or successfully cleared.

Can a Paragraph IV generic challenge LUPKYNIS using excipient changes alone?

Executive answer: A Paragraph IV filing is evaluated against the listed patents. Excipient changes do not automatically remove exposure because infringement analysis often centers on the API and any claimed formulations/processes.

Practical Paragraph IV logic for capsule products

A generic would typically need:

Bioequivalence strategy aligned with dissolution and absorption.
API form equivalence (same polymorph/solid form if claimed or if the NDA requires a specific form).
Formulation parity sufficient for BE but with permissible flexibility.

Excipient swaps can help to:

achieve dissolution alignment,
improve manufacturability,
reduce sensitivity to humidity and heat.

But they are unlikely to replace a true patent-clearing strategy.

What is the Orange Book status of LUPKYNIS patents, and how many formulation or process patents are listed?

Executive answer: The Orange Book listing controls filing and litigation posture. Formulation- and process-type patents matter most for excipient strategy and for whether a “different capsule composition” design-around is plausible.

What to extract from Orange Book listings (commercially actionable items)

For LUPKYNIS, an investor-grade assessment requires the Orange Book table of:

Patent numbers and expiration dates
Patent types (composition of matter, method of use, formulation, etc.)
Listing status (active, expired, withdrawn, expired-within-year)
Associated NDA and dosage form mapping (capsules strength-by-strength)

Why this matters

If multiple patents are listed on a capsule dosage form, then excipient changes may still face infringement unless they also clear each relevant claim scope.

Are there biosimilar opportunities for LUPKYNIS, or is it purely a generic small-molecule market?

Executive answer: LUPKYNIS is a small-molecule drug (voclosporin), not a biologic. Biosimilar pathways do not apply in the same way as for monoclonal antibodies or other biologics.

Commercial implication

The competitive field is generics and potentially authorized generics or reformulated versions that do not change active identity.
Excipient strategy affects generic manufacturability and BE, not biosimilar “similarity” arguments.

What excipient reformulation opportunities exist: moisture protection, stability, and patient-experience upgrades?

Executive answer: The most credible commercial opportunities for excipient-driven reformulation focus on stability and manufacturability rather than therapeutic performance claims.

1) Moisture-stability and packaging-driven differentiation

Capsules that are sensitive to humidity often benefit from:

excipient combinations that buffer moisture uptake,
desiccant strategies during packaging,
tighter control of water activity and headspace specifications.

Commercial upside: reduced variability, lower batch failures, and potentially improved shelf life or reduced supply risk.

2) Improved dissolution with regulatory BE targets

If the original formulation uses disintegrants and solubilizers in a specific manner, reformulators can:

tune disintegration time and dissolution slope,
shift dissolution behavior within acceptable BE bounds.

Commercial upside: reduces bioequivalence failure risk and accelerates development timelines.

3) Manufacturing robustness for scale and cost

Excipient strategy often targets:

powder flow to reduce die/wheel loading variability (if any compression steps exist),
lubrication to reduce sticking and tooling wear,
consistent capsule fill weights.

Commercial upside: reduces COGS and rejects, especially in high-throughput manufacturing.

How does LUPKYNIS excipient strategy compare with other calcineurin inhibitor formulations (e.g., tacrolimus, cyclosporine)?

Executive answer: Calcineurin inhibitors share formulation constraints: moisture control, dissolution predictability, and sensitivity to processing conditions. However, differences in chemical structure and salt forms mean excipient systems are not interchangeable across products.

Common patterns across oral calcineurin inhibitors

use of disintegrants and/or solubilizers to control dissolution,
careful choice of lubricants and flow agents to support capsule filling,
stability planning for humidity and temperature.

Commercial takeaway: reformulation opportunities for LUPKYNIS are best evaluated through dissolution and stability engineering work rather than importing excipient recipes from unrelated brands.

Which companies are positioned to exploit excipient and formulation design-around for LUPKYNIS?

Executive answer: The competitive field is typically dominated by established generic manufacturers with capsule solid-dosage expertise and strong formulation development capabilities. Excipient-driven development is usually performed by in-house formulation teams or through development alliances with contract development and manufacturing organizations (CDMOs).

What to screen for in target-company dossiers

capsule development track record,
solid-state characterization capabilities,
humidity-stress testing and stability-indicating method maturity,
experience managing bioequivalence risk across moisture-sensitive actives.

What patent litigation affects LUPKYNIS generic or reformulation entry, and where do excipients fit in?

Executive answer: Litigation posture depends on which patents are asserted and whether the generic’s capsule formulation is accused under formulation/process claims. Excipient changes are most relevant when the asserted patents involve manufacturing methods or specific composition elements.

Litigation failure modes for reformulators

asserting that excipient changes avoid infringement when asserted claims are broad to the capsule composition,
relying on dissolution similarity without matching solid-state attributes,
underestimating how manufacturing steps with excipients are treated in infringement analysis.

Business implication: excipient work must be connected to claim-by-claim infringement design-around, not limited to BE development.

What licensing and settlement pathways exist for LUPKYNIS, and how can excipient concessions monetize them?

Executive answer: Commercially, the most feasible monetization pathways are licensing and supply arrangements in exchange for market entry timing and reduced litigation risk. Excipient concessions can matter as part of negotiated development, including agreed formulation specs that reduce bioequivalence and quality risk.

Where excipient concessions show up in deals

agreed dissolution profile targets that support BE and labeling,
agreed stability and moisture control requirements,
agreed manufacturing method constraints that reduce litigation risk.

Commercial logic: settlements often trade speed and certainty. Excipient-driven specifications can reduce the “unknowns” that cause delay.

What manufacturing and regulatory barriers arise when changing excipients in a capsule like LUPKYNIS?

Executive answer: The barriers are:

quality system requirements for formulation changes,
BE requirements if excipient-driven formulation differences change dissolution,
potential solid-state requalification if the active is impacted by processing.

Regulatory posture

For a generic:

formulations must support BE with the reference product. For a reformulation by a brand:
changes typically require CMC supplements and stability bridging, with tight demonstration that performance remains consistent.

Quality and CMC hotspots

dissolution and disintegration specs aligned with reference product,
water activity control and stability-indicating assay performance,
impurity profile comparability if processing is modified.

Commercial opportunity sizing: where excipient strategy creates value in the LUPKYNIS lifecycle

Executive answer: Excipient strategy creates value along three commercial levers: (i) reducing time-to-market for generics after patent clearance, (ii) lowering manufacturing cost and reducing batch failure rates, and (iii) enabling patient-experience or supply-chain improvements that sustain share during brand life-cycle.

Opportunity map

Opportunity type	Best timing	What excipient work improves	Main gating factor
Authorized generic / supply partnership	Pre-expiry	BE robustness, stability	Patent clearance and deal terms
At-risk reformulation (brand line extension)	Pre-expiry	Stability shelf-life, manufacturability	Patent claims and CMC scope
Post-expiry generic launch	Post-Orange Book/patent expiry	BE success rate, cost	Patent clearance plus FDA approval
Contract manufacturing differentiation	Pre- and post-entry	Batch yield, quality margins	Validation and comparability requirements
Niche market variants (strengths, packaging, labeling)	Post-entry	Supply reliability	Clinical/label constraints and CMC

Key Takeaways

Excipient strategy for LUPKYNIS is primarily a technical and CMC lever that can reduce bioequivalence risk, improve stability, and lower manufacturing cost.
Excipient swaps do not replace a patent-clearing plan where Orange Book-listed formulation/process or method patents remain in force.
The highest-probability commercial pathway is authorized supply/partnered entry or post-expiry generic launch preparation, using excipient engineering to improve BE success and manufacturing performance.
Litigation and settlement outcomes are claim- and process-driven; excipient decisions must map to asserted claim scope and manufacturing steps, not only to dissolution outcomes.

FAQs

How do moisture-stability excipients reduce bioequivalence failure risk for capsule generics?
When do generic developers need to match the reference product’s disintegration and dissolution profile closely for voclosporin?
What formulation and CMC sections are most scrutinized when changing capsule excipients from an approved reference product?
Can reformulation into alternative capsule fills or different packaging create meaningful supply-chain advantages without BE rework?
Which solid-state characterization tests most affect excipient-based reformulation success for moisture-sensitive small molecules?

References

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
FDA. Guidance for Industry: Bioavailability and Bioequivalence Studies for Nasal Spray and Inhalation Solution, and Other Oral Formulations. U.S. Food and Drug Administration.
FDA. Guidance for Industry: Changes to an Approved NDA or ANDA. U.S. Food and Drug Administration.

More… ↓

⤷ Start Trial